CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lyra Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lyra Therapeutics Inc
480 Arsenal Way
Phone: (617) 373-4600p:617 373-4600 WATERTOWN, MA  02472  United States Ticker: LYRALYRA
Business Summary
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Harlan W.Waksal 70 2/17/2022 2/17/2022
President, Chief Executive Officer, Director MariaPalasis 58 1/1/2015
Chief Financial Officer, Treasurer, Secretary JasonCavalier 50 9/12/2021 9/12/2021
10 additional Officers and Directors records available in full report.

Business Names
Business Name
LYRA
Lyra Therapeutics Security Corporation

General Information
Number of Employees: 88 (As of 12/31/2023)
Outstanding Shares: 59,743,123 (As of 3/1/2024)
Shareholders: 68
Stock Exchange: NASD
Federal Tax Id: 841700838
Fax Number: (302) 655-5049
Email Address: contactus@lyratx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024